Studies in which LAG3 is targeted, mostly in combination with other IC inhibitors, are currently conducted for several tumor types such as melanoma, multiple myeloma (NCT04150965), colon cancer (NCT03978611) or lung cancer (NCT04623775) [42]. Here, LAG3 is linked to malignant colon neoplasm.